Adenosine as an adjunct to standaard blood cardioplegia

Phase 1

• Conditions: Post-operative cardiac damage in patients scheduled for minimal invasive, port-access operations; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2015-001923-22-NL
• Lead Sponsor: Amphia Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-11-19
• Last Update Posted: 25 November 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

• Gender; male/ female
• Age: = 18 year
•Elective cardiac surgical patients: - minimally invasive, port access surgery (mitral valve surgery)

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 50
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from participation in this study:
•All non-minimally invasive surgery
•Theophylline or dipyridamole use
•Caffeine use up to 12 hours prior to surgery

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified